IMVTImmunovant, Inc.vs its industry peers
A metric-by-metric comparison of Immunovant, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMVTEsta | $7.5B#5 | — | 10.2x#4 | — | — | -22.2%#4 | — | -68.8%#7 | — | — | 138.2%#4 | — |
| MRNA | $58.1B#1 | — | 8.6x#3 | 29.9x#2 | -39.9%#4 | 20.8%#3 | -158.1%#2 | -41.7%#5 | -54.6%#3 | — | 486.2%#2 | — |
| TWST | $9.0B#4 | — | 20.1x#7 | 23.8x#1 | 20.3%#3 | 62.8%#1 | -36.2%#1 | -17.4%#3 | -41.4%#2 | — | — | — |
| ERAS | $5.4B#8 | — | 14.9x#5 | — | — | 23.0%#2 | — | -34.4%#4 | — | — | 804.7%#1 | — |
| RVMD | $42.0B#2 | — | 16.1x#6 | — | — | -88.5%#7 | — | -43.4%#6 | — | — | 338.6%#3 | — |
| CGON | $6.6B#6 | — | 6.4x#2 | 1627.1x#4 | 254.7%#2 | -82.9%#6 | -4722.1%#4 | -15.6%#2 | -18.8%#1 | — | — | — |
| DNTH | $5.7B#7 | — | 4.9x#1 | 2815.7x#5 | -67.3%#5 | -91.1%#8 | -8739.3%#5 | -13.9%#1 | — | — | — | — |
| CYTK | $9.6B#3 | — | — | 109.6x#3 | 376.6%#1 | -33.2%#5 | -695.4%#3 | — | — | — | 39.5%#5 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice